2型糖尿病患者心率变异性与自主神经病变研究

目的研究2型糖尿病(T2DM)患者心率变异性(HRV)与自主神经病变关系。方法50例2型糖尿病患者按病程长短分成2组:病程>10年组(Ⅰ组)27例,病程<10年组(Ⅱ组)23例;健康对照组(Ⅲ组)25例。测定每例HRV时域指标,3组对比分析。结果3组HRV降低发生率分别为62.96%、8.70%、0.00%,差异具有显著性;3组SDNN、SDANN Index、SDNN Index各组间比较差异均有显著性;rMSSD、PNN50 I组与III组比较差异具有显著性,II组与III组比较差异无统计学意义。结论HRV是早期判定T2DM患者自主神经病变指标,T2DM患者交感神经张力明显增高,随病程延长,迷走神经功能有不同程度损害。     

抑郁症焦虑症患者心率变异性特点的对比研究

目的探讨抑郁症、焦虑症患者自主神经功能的特点。方法随机选择42例抑郁症患者,10例焦虑症患者和17例健康对照者分别接受短时心率变异性分析,记录相关考察指标,进行统计学分析。结果心率变异性分析的各项考察指标中,各观察组均有一项或多项低于正常对照组（P〈0．05）;且各组之间互相对比分析P〈0．05。结论抑郁症、焦虑症患者均存在心率变异性的降低,其自主神经功能活性降低。抑郁症患者因伴或不伴有焦虑症状,其心率变异指标不同,可以指导治疗。     

躯体化症状为主的抑郁症心率变异性对照研究

目的：探讨躯体化症状为主的抑郁症患者自主神经系统的特点及抑郁症躯体化表现的发生机制。方法：对30例躯体化症状为主的患者（A组）和30例情绪症状为主的患者（B组）及30例健康正常者（C组）分别进行汉密尔顿抑郁量表（HAMD）和汉密尔顿焦虑量表（HAMA）评定及短时（10min）心率变异性（HRV）分析。结果：A、B、C3组HRV分析指标RR间期标准差（SDNN）分别为（50.84±19.92）ms、（94.93±28.80）ms、（105.77±22.05）ms,A组显著低于C组（t=5.68,P〈0.01）,较B组低（t=3.73,P〈0.05）;3组LF/HF分别为（6.26±2.11）ms、（3.51±2.44）ms、（1.80±1.07）ms,A组显著高于C组（t=6.35,P〈0.01）,较B组高（t=2.50,P〈0.05）;A组HAMD评分（28.30±6.26）分高于B组（24.35±6.69）分,二者差异有显著性（t=3.14,P〈0.05）;A组HAMA评分（22.70±4.92）分显著高于B组（13.05±4.71）分,二者差异有显著性（t=6.17,P〈0.01）;HAMD焦虑/躯体化因子分与HRV指标SDNN、LF、HF、VLF和LF/HF均呈中度相关（r分别为0.49、0.61、0.58、0.50、0.63）（P〈0.05或P〈0.01）。结论：躯体化症状表现为主的抑郁症患者多伴有焦虑,自主神经功能紊乱。     

大剂量甲钴胺对糖尿病患者心率变异性影响的评价

目的：评价应用大剂量甲钴胺对糖尿病患者心率变异性的影响。方法：收集糖尿病患者64例,分为治疗组和对照组,治疗组患者静脉注射甲钴胺1mg,每天2次,连用2周后改为口服0．5mg,每天3次。总疗程为4周。运用24h动态心电图检测所有患者在治疗前后心率变异性指标的变化,明确甲钴胺治疗糖尿病心脏自主神经病变的疗效。结果：治疗组心率变异性各项指标治疗4周后较治疗前有显著提高,自主神经症状明显好转,与对照组比有显著统计学意义（P〈0．01）。结论：甲钴胺治疗糖尿病心脏自主神经病变的疗效显著,可以改善患者的心率变异性。     

抑郁症与精神分裂症患者心率变异性的对照分析

目的探讨抑郁症与精神分裂症患者的心率变异性（HRV）的差异。方法对36例首次发作的抑郁症患者及年龄、性别与之相匹配的41例首次发作的精神分裂症患者分别进行短时程HRV检测,并对其心率变异指标SDNN、MSD、rMSSD、PNN50、LF、HF、LF/HF结果进行分析。结果抑郁症患者的时阈指标rMSSD（P〈0.05）、PNN50（P〈0.01）较精神分裂症显著降低,而两者之间的频阈分析指标无明显差异。结论抑郁症患者的自主神经功能失调较精神分裂症患者更严重。     

糖尿病合并冠心病、脑卒中患者心率变异性频域分析

对48例糖尿病合并冠心病,脑卒中患者进行心率变异性频域分析（HRSA）与30例糖尿病无合并症组对照,发现观察组中HRSA频谱成分明显长于正常组,HRSA是早期发现糖尿病合并冠心病,脑卒中患者植物神经功能紊乱的敏感方法。     

氟西汀联合舒肝解郁胶囊治疗抑郁症的效果及对患者心率变异性的影响

背景 抑郁症可能导致患者存在较高的自杀风险,严重影响患者和家属的生活质量,给社会带来较大负担。虽然西药中的抗抑郁药疗效确切,但单一使用对抑郁症状改善相对局限,且联用两种抗抑郁药可能增加不良反应。中成药与西药合理配伍使用可能起到相辅相成的效果,且中成药安全性较高。目的 探讨氟西汀联合舒肝解郁胶囊治疗抑郁症的效果,比较氟西汀联合舒肝解郁胶囊与单用氟西汀的疗效、安全性以及对患者心率变异性影响的差异,为抑郁症患者的临床用药提供参考。方法 收集2015年12月-2016年6月在新乡医学院第二附属医院门诊就诊和住院治疗的、符合《精神障碍诊断与统计手册（第5版）》（DSM-5）抑郁症诊断标准的64例患者为研究对象,采用随机数字表法分为联合用药组和氟西汀组各32例。两组均接受氟西汀治疗,联合用药组在此基础上联用舒肝解郁胶囊。治疗前,两组均接受汉密尔顿抑郁量表24项版（HAMD-24）和汉密尔顿焦虑量表（HAMA）评定以及心率变异性（HRV）分析,并于治疗第2、4、6周末接受HAMD-24和副反应量表（TESS）评定,治疗第6周末再次进行HRV分析。结果 最终共60例抑郁症患者完成研究,联合用药组和氟西汀组各30例。治疗第2、4、6周末,联合用药组HAMD-24评分均低于氟西汀组,差异均有统计学意义（t=-2.677、-3.960、-4.432,P<0.05或0.01）。与治疗前相比,联合用药组在治疗第6周末24小时平均正常RR间期标准差（SDNN）、标化低频功率（nLF）以及标化高频功率（nHF）均较高（t=-73.970、-31.878、-38.721,P均<0.01）,而低频功率与高频功率之比（LF/HF）较低（t=3.525,P<0.01）。治疗第6周末,联合治疗组总有效率高于氟西汀组,差异有统计学意义（86.67% vs. 70.00%,χ²=18.764,P<0.01）。治疗第2、4、6周末,两组不良反应发生例数差异均无统计学意义（P均>0.05）。结论 与单用氟西汀相比,舒肝解郁胶囊联合氟西汀对抑郁症的临床疗效和改善患者心率变异性方面可能更好,且不增加不良反应。     

复发性抑郁症与长期住院精神分裂症患者的心率变异性差异

目的 比较复发性抑郁症与长期住院精神分裂症患者之间心率变异性（HRV）的差异。 方法 回顾性连续纳入2014 年1 月至2019 年1 月于上海交通大学医学院附属精神卫生中心精神科住 院治疗的多次发作的抑郁症或长期住院精神分裂症患者各120 例,两组患者性别、年龄相匹配。对两 组患者分别开展HRV 检测,使用24 h 动态心电图记录仪和心率变异分析软件进行检测,并对HRV相关 指标R-R间期标准差（ SDNN）、相邻R-R间期差值的均方根（ rMSSD）、相邻R-R间期之间差值＞50 ms的 百分比（PNN50）、低频功率（LF）、高频功率（HF）、LF与HF之间的比值（LF/HF）的结果进行组间比较。采 用Spearman 相关分析分析两组患者住院次数与HRV 各指标的相关性。结果 复发性抑郁症患者组时 阈指标SDNN 高于长期住院精神分裂症组［121.0（95.0,158.0）比111.0（87.0,144.0）ms,t=2.214］,rMSSD、 PNN50 低于长期住院精神分裂症组［22.0（13.0,46.0）比20.0（12.0,28.0）ms,t=3.832;3.0（0,13.0）% 比2.0（0, 7.0）%,t=2.571］,差异均有统计学意义（均P＜ 0.05）;两组频阈指标差异无统计学意义（均P＞ 0.05）。进 一步采用Spearman 相关分析结果显示,复发性抑郁症患者住院次数与rMSSD（r=0.270,P=0.003）、PNN50 （r=0.263,P=0.004）、HF（r=0.246,P=0.015）相关,但精神分裂症患者住院次数与HRV各分析指标无相关（均 P＞ 0.05）。结论 复发性抑郁症患者的自主神经功能失调较长期住院精神分裂症患者严重,复发性抑 郁症患者的住院次数影响患者HRV时阈指标     

焦虑症患者心率变异性的相关研究

目的:探讨焦虑症患者心率变异性异常的一些相关影响因素。方法:选取焦虑症患者(焦虑症组)80例和健康志愿者(正常对照组)80名完成一般情况问卷及病史问卷、汉密顿抑郁量表(HAMD)、汉密顿焦虑量表(HAMA)评定,同时采用24小时动态心电图记录器测定两组被试心率变异性(HRV)指标,并进行比较。结果:焦虑症组平均心率显著高于正常对照组(t=6.79,P<0.01)。焦虑症组HRV所有指标均低于对照组(P<0.05或P<0.01),其中SDNN、RMSSD、PNN50、HF及LF/HF与对照组相比差异有统计学意义(t分别=-11.95,-5.34,-4.79,-2.69,-2.93;P均<0.01)。不同性别(F=5.500)、不同年龄段(F=270.39)两组被试平均心率指标差异有统计学意义(P<0.05或P<0.01)。结论:焦虑症患者自主神经功能紊乱与性别、年龄有关。     

抑郁症患者的皮质醇、甲状腺功能及心率变异性特征对照研究

目的研究抑郁症患者的皮质醇、甲状腺功能及心率变异性特点,探讨其与躯体症状、失眠及性别因素的关系。方法检测60例抑郁症患者和60名正常对照的血清皮质醇(Cortisol,COR)、三碘甲状腺原氨酸(triiodothyronine,T3)、四碘甲状腺原氨酸(tetraiodothyronine,T4)、促甲状腺素(Thyroid stimulating hormone,TSH)水平,当日进行心率变异性检查,进行两组的比较,并按照躯体症状、失眠及不同性别进行分组比较。结果患者组的R-R间期平均标准差(standard deviation of average RR intervals,SDNN)、低频功率(low frequen-cy band,LF)、高频功率(high frequency band,HF)分别为[(34.21±14.31),186.64(846.67,113.87),125.00(839.22,48.50],对照组依次为[(43.86±12.61),375.92(2542.70,233.08),247.51(1547.36,142.33)],前者显著低于后者(均P<0.01)。与对照组相比,患者组COR水平增高[(15.35=6.45)vs.(11.81±6.32),P<0.01],TSH、T3及T4水平无显著差异(P>0.05)。伴躯体症状患者组COR水平显著高于对照组及不伴躯体症状组(P<0.01),SDNN、LF及HF指数均显著低于后两组(P<0.01)。伴失眠的患者组血清COR水平显著高于对照组及不伴失眠组(均P<0.01),SDNN、LF及HF指数均显著低于后两组(均P<0.05)。男性患者组SDNN、LF、HF指数均显著低于正常男性组(均P<0.05);女性患者组血清COR水平显著高于正常女性组(P<0.01),SDNN、LF指数均显著低于正常女性组(均P<0.05)。结论抑郁症HPT轴无紊乱,仅HPA轴及自主神经功能出现紊乱,且HPA轴激素水平及心率变异性与躯体症状、失眠及性别因素有关。     

米氮平对2型糖尿病患者合并抑郁症的疗效观察

目的 探讨果氮平对2型糖尿病患者合并抑郁症的疗效.方法 将120例合并抑郁症的2型糖尿病患者,随机分为研究组和对照组,每组60例.对照组仅用降糖药治疗,研究组在常规降糖药治疗基础上联用米氮平( 15～45mg/d)治疗,治疗8周.在治疗前和治疗8周末均进行汉密尔顿抑郁量表(HAMD)评定和空腹血糖、餐后2h血糖、糖化血...     

舍曲林联合重复经颅磁刺激对老年2型糖尿病患者伴抑郁的疗效观察

目的 观察舍曲林联合重复经颅磁刺激(rTMS)对老年2型糖尿病伴抑郁患者的治疗效果.方法 选择2017-05—2020-08郑州大学第一附属医院老年内分泌科老年2型糖尿病伴抑郁患者120例,根据抛硬币法随机分为舍曲林联合重复经颅磁刺激组(联合组)和舍曲林单药治疗组(单药组)各60例,观察8周,联合组随访到53例,单药组...     

社区老年2型糖尿病患者共病抑郁的现况调查及相关危险因素分析

目的 了解社区老年2型糖尿病人群伴发抑郁的现状及相关危险因素.方法 选取2015年1月~2016年12月在上海市梅陇社区卫生服务中心就诊的550例老年2型糖尿病(T2DM)患者进行病人健康问卷抑郁量表(PHQ-9)评定及相关问卷调查,根据PHQ-9评分情况将患者分为共病抑郁组和非抑郁组,对两组患者人口学资料进行比较,采用多因素Logistic回归分析探讨糖尿病共病抑郁的相关危险因素.结果 所调查老年2型糖尿病人群抑郁的发生率为45.27%;糖尿病病程、合并躯体疾病数、空腹血糖、HbA1C为社区老年T2DM患者共病抑郁的独立危险因素(P<0.05).结论 老年T2DM患者中抑郁的发病率高,在对社区老年T2DM患者进行指导、治疗时,除了需要积极控制血糖、HbA1C外,还需要积极关注其可能存在的抑郁症状,做到前期预防、早期发现并及时治疗.     

Brain lesions on MRI in elderly patients with type 2 diabetes mellitus

BACKGROUND AND PURPOSE: Diabetes mellitus (DM) type 2 has been associated with poor cognitive performance and dementia, particularly in elderly patients. The exact mechanisms underlying the cognitive dysfunction in DM remain unclear. Imaging studies of the brain could be helpful to give more insight into possible structural brain lesions underlying these cognitive dysfunctions. Therefore, we performed a study in independently living patients with DM type 2 in order to investigate the association between DM and brain imaging abnormalities. METHODS: The study population consisted of 45 patients with DM type 2 without hypertension (mean age 73.4 +/- 5.1 years, mean duration 16.5 +/- 11.5 years), 45 patients with DM type 2 and hypertension (mean age 73.5 +/- 6.1 years, mean duration 11.9 +/- 9.2 years) and 44 control subjects (mean age 73.1 +/- 5.4 years). All patients and control subjects underwent an MRI of the brain. White matter lesions (WML), cerebral atrophy and medial temporal lobe atrophy were rated by a standardized visual rating scale. Lacunar infarcts were defined as focal hypo-intensities on fluid-attenuated inversion recovery sequences with a hyperintense rim around it. RESULTS: WML occurred more frequently in diabetic patients with hypertension as well as without hypertension. Significantly more deep WML were found in DM patients with and without hypertension when compared to control subjects, whereas no difference was found in the occurrence of periventricular hyperintensities. In all 3 groups, lacunar infarcts occurred sporadically. A trend towards higher atrophy scores was seen in patients with DM compared to control subjects. CONCLUSIONS: The data of this cross-sectional study suggest that type 2 DM is an independent risk factor for deep WML in the independently living elderly patients.     

Short-term heart rate complexity is reduced in patients with type 1 diabetes mellitus

OBJECTIVE: The aim of this study was to test whether new heart rate variability (HRV) complexity measures provide diagnostic information regarding early subclinical autonomic dysfunction in diabetes mellitus (DM). METHODS: HRV in DM type 1 patients (n=17, 10f, 7m) aged 12.9-31.5 years (duration of DM 12.4+/-1.2 years) was compared to a control group of 17 healthy matched probands. The length of R-R intervals was measured over 1h using a telemetric ECG system. In addition to linear measures, we assessed HRV complexity measures, including multiscale entropy (MSE), compression entropy and various symbolic dynamic measures (Shannon and Renyi entropies, normalized complexity index (NCI), and pattern classification). RESULTS: HRV magnitude was significantly reduced in patients with DM. Several HRV complexity parameters (MSE at scales 2-4, Renyi entropy, NCI) were also significantly reduced in diabetics. MSE indices and compression entropy did not correlate with linear measures. CONCLUSIONS: The magnitude and complexity of HRV are reduced in young patients with DM, indicating vagal dysfunction. SIGNIFICANCE: The quantification of HRV complexity in combination with its magnitude may provide an improved diagnostic tool for cardiovascular autonomic neuropathy in DM.     

帕罗西汀对2型糖尿病伴发抑郁患者疗效观察

目的评价帕罗西汀对2型糖尿病伴发抑郁患者抑郁、焦虑症状的疗效及安全性。方法对45例2型糖尿病伴发抑郁患者给予帕罗西汀治疗12周,采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、MOS健康状况调查问卷(SF-36)评定疗效,采用副反应量表(TESS)和相关实验室检查评定安全性。结果帕罗西汀能明显改善2型糖尿病伴发抑郁患者抑郁、焦虑症状,治疗后患者生活质量明显提高；无明显副反应。结论帕罗西汀对2型糖尿病伴发抑郁患者的治疗安全有效。     

Rosiglitazone influences adipose tissue distribution without deleterious impact on heart rate variability in coronary heart disease patients with type 2 diabetes

Introduction

Obesity is associated with decreased heart rate variability (HRV). Rosiglitazone, a PPARγ agonist, is generally associated with increases in body mass.

Purpose

To assess whether the gain in body mass and adiposity expected from rosiglitazone treatment has an influence on HRV in patients with type 2 diabetes and coronary artery disease.

Methods

One hundred and twenty-five patients with type 2 diabetes and coronary artery disease aged between 40 and 75 years were studied. Anthropometric measurements: (1) body mass index (BMI), (2) waist circumference (WC), (3) abdominal computed tomography (CT) scan, and HRV (using a 24 h Holter) were measured at baseline and after 12 months of treatment. Patients were randomized to rosiglitazone or placebo regimen.

Results

In the rosiglitazone vs. placebo group, there were significant increases in body mass [3.5 (2.6;4.4); mean (95 % CI) vs. 0.2 (?0.4;0.8)] kg), BMI [1.3 (1.0;1.6) vs. 0.1 (?0.1;0.3) kg/m²], WC [2.1 (0.9;3.3) vs. 0.4 (?0.4;1.2) cm, all p ≤ 0.001] and subcutaneous adipose tissue [253 (187;319) vs. 6 (?24;36) cm³, p ≤ 0.001] without statistically significant changes in visceral adipose tissue [?22 (?91;47) vs. 57 (43;71) cm³, p = 0.546], respectively. There was no change in HRV in either group after 12 months. There were no correlations between changes in HRV variables and fat distribution.

Conclusion

Our results suggest that changes in adiposity indices observed after 12 months of rosiglitazone therapy have no deleterious influence on HRV in patients with type 2 diabetes and coronary artery disease.

     

Asymmetrical properties of heart rate variability in type 1 diabetes

Heart rate variability related to heart rate decelerations and accelerations is reduced in patients with type 1 diabetes compared to healthy individuals both in resting 10-min and ambulatory 24-h ECGs.